Gravity Reports Third Quarter of 2017 Results and Business Updates
October 30, 2017 06:20 ET | GRAVITY Co., Ltd.
Seoul, Korea, Oct. 30, 2017 (GLOBE NEWSWIRE) -- GRAVITY REPORTS THIRD QUARTER OF 2017 RESULTS AND BUSINESS UPDATES Seoul, South Korea – October 30, 2017 – GRAVITY Co., Ltd. (NasdaqCM: GRVY)...
Gravity Reports Second Quarter of 2017 Results and Business Updates
August 09, 2017 06:20 ET | GRAVITY Co., Ltd.
Seoul, Korea, Aug. 09, 2017 (GLOBE NEWSWIRE) -- GRAVITY REPORTS SECOND QUARTER OF 2017 RESULTS AND BUSINESS UPDATES Seoul, South Korea – August 9, 2017 – GRAVITY Co., Ltd. (NasdaqCM: GRVY)...
Great Basin Scientific Provides Business Update
June 26, 2017 07:00 ET | Great Basin Scientific, Inc.
New Business Pipeline exceeds $5.0 million in potential new revenue; Nearly $2.0 million in potential pipeline revenue is from Stool Bacterial Pathogens Panel, currently awaiting FDA clearance SALT...
Gravity Reports FIRST Quarter of 2017 Results and Business Update
April 28, 2017 16:00 ET | GRAVITY Co., Ltd.
Seoul, Korea, April 28, 2017 (GLOBE NEWSWIRE) --      ...
galectin.jpg
Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update
March 28, 2017 08:30 ET | Galectin Therapeutics
NORCROSS, Ga., March 28, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
galectin.jpg
Galectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
March 21, 2017 08:30 ET | Galectin Therapeutics
NORCROSS, Ga., March 21, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will...
galectin.jpg
Galectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update
November 08, 2016 08:00 ET | Galectin Therapeutics
NORCROSS, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...
galectin.jpg
Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis
September 27, 2016 16:15 ET | Galectin Therapeutics
Larger Phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled Closed private placement financing for $1.5 million Conference call to be held today at 5:30 p.m. (Eastern Time) ...
galectin.jpg
Galectin Therapeutics Reports Second Quarter 2016 Financial Results and Provides Business Update
August 09, 2016 08:00 ET | Galectin Therapeutics
Top-line data from NASH-FX trial in NASH patients with advanced fibrosis expected to be reported by the end of September Australian patent allowance strengthens global intellectual property...
SANUWAVE Health Reports First Quarter Financial Results and Provides a Business Update
May 17, 2016 09:00 ET | SANUWAVE Health, Inc.
ALPHARETTA, Ga., May 17, 2016 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB:SNWV), reported financial results for the three months ended March 31, 2016 and provided a business update on Monday,...